823188-58-5 Usage
General Description
"(R)-2-(2-Chlorophenyl)pyrrolidine" is a chemical compound with a chiral center characterized by its complex molecular structure. (R)-2-(2-Chlorophenyl)pyrrolidine is comprised of a pyrrolidine ring, a type of heterocyclic amine, bonded to a chlorophenyl group. Its precise structure involves a phenyl ring bonded to the 2-carbon of the pyrrolidine ring, with a chlorine atom substituted at the 2-position of the phenyl ring. This chemical compound is mostly used in research and development activities in various scientific institutes and laboratories. Being a chiral compound, it often plays a crucial role in the synthesis of pharmaceutical drugs due to the importance of chirality in drug efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 823188-58-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,2,3,1,8 and 8 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 823188-58:
(8*8)+(7*2)+(6*3)+(5*1)+(4*8)+(3*8)+(2*5)+(1*8)=175
175 % 10 = 5
So 823188-58-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H12ClN/c11-9-5-2-1-4-8(9)10-6-3-7-12-10/h1-2,4-5,10,12H,3,6-7H2/t10-/m1/s1
823188-58-5Relevant articles and documents
Zinc-Catalyzed Asymmetric Hydrosilylation of Cyclic Imines: Synthesis of Chiral 2-Aryl-Substituted Pyrrolidines as Pharmaceutical Building Blocks
W?glarz, Izabela,Michalak, Karol,Mlynarski, Jacek
supporting information, p. 1317 - 1321 (2020/12/09)
The first successful enantioselective hydrosilylation of cyclic imines promoted by a chiral zinc complex is reported. In situ generated zinc-ProPhenol complex with silane afforded pharmaceutically relevant enantioenriched 2-aryl-substituted pyrrolidines in high yields and with excellent enantioselectivities (up to 99% ee). The synthetic utility of presented methodology is demonstrated in an efficient synthesis of the corresponding chiral cyclic amines, being pharmaceutical drug precursors to the Aticaprant and Larotrectinib. (Figure presented.).
TACHYKININ RECEPTOR ANTAGONISTS
-
Page 41, (2010/02/10)
The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
